Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition

• Status: Completed
• Trial end date: 2019-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

This trial investigates effects of a glucagon bolus injection on heart rate, blood pressure and cardiac output during beta-blocker-induced cardiodepression. Furthermore, the effects of two different doses of intravenous glucagon on hemodynamic parameters are explored.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital Bispebjerg and Frederiksberg
• Treatments: Adrenergic beta-Antagonists; Esmolol; Glucagon; Glucagon-Like Peptide 1; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Healthy male determined by investigator, based upon physical examination, medical history, ECG, vital signs and laboratory results

• Body mass index (BMI) ≥ 18.5 and ≤ 29.9 kg/m2 and body weight between 50 and 100 kg, inclusive, at screening visit.

Exclusion Criteria:

• Abnormal blood levels of sodium, potassium, creatinine, alanine transaminase (ALT), alkaline phosphatase, albumin, bilirubin, hemoglobin, HbA1c, cholesterol fractions.

• Bradycardia (<45 beats per minute)

• Hypotension (systolic blood pressure < 100 mmHg)

• Second or third degree atrioventricular conduction delay

• Sick sinus syndrome

• Any heart disease or hypertension

• Pheochromocytoma

• Allergy to any active or inactive ingredient contained in investigatory medicines or tools.

• Raynaud's syndrome

• Prinzmetal's angina

• Diabetes

• Pulmonary disease

• Pheochromocytoma

• Any contraindication against investigatory medicines or tools.